Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

Core Insights - Genelux Corporation, a late clinical-stage immuno-oncology company, will present its clinical-stage programs and upcoming milestones at the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024 [1][2] Company Overview - Genelux is focused on developing next-generation oncolytic immunotherapies for patients with aggressive and difficult-to-treat solid tumors [4] - The company's leading product candidate, Olvi-Vec, is a modified strain of the vaccinia virus currently in a Phase 3 trial for platinum-resistant/refractory ovarian cancer [4] - Olvi-Vec is being evaluated in a multicenter, randomized, open-label trial comparing its efficacy and safety in combination with platinum-doublet and bevacizumab against physician's choice of chemotherapy and bevacizumab [4] - The company utilizes its proprietary CHOICE™ platform to develop a library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec [4] Conference Details - Thomas Zindrick, President, Chairman, and CEO of Genelux, will engage in a fireside chat scheduled for September 11, 2024, at 12:30 p.m. ET [2] - The conference will also include virtual one-on-one meetings for institutional investors interested in discussing with Genelux management [3]